Overview

An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.
Phase:
Phase 3
Details
Lead Sponsor:
Medivation, Inc.
Collaborator:
Pfizer